Neuland Laboratories

Neuland Laboratories Debt

The Debt of Neuland Laboratories (NEULANDLAB.NS) as of Nov 7, 2026 is 3.01 B INR. In the previous year, Debt was 1.57 B INR — a change of 91.73% (higher).

Debt

3.01 BINR

YoY

91.73%

Last updated:

In 2026, Neuland Laboratories's total debt was 3.01 B INR, a 91.73% change from the 1.57 B INR total debt recorded in the previous year.

The Neuland Laboratories Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2019
2.31 B INR
Jan 1, 2020
2.64 B INR
Jan 1, 2021
1.82 B INR
Jan 1, 2022
2.41 B INR
Jan 1, 2023
1.28 B INR
Jan 1, 2024
953.90 M INR
Jan 1, 2025
1.57 B INR
Jan 1, 2026
3.01 B INR
The Neuland Laboratories Debt history
YEARDebtYoY
3.01 BINR+91.73%
1.57 BINR+64.73%
953.90 MINR-25.74%
1.28 BINR-46.60%
2.41 BINR+31.95%
1.82 BINR-30.88%
2.64 BINR+13.94%
2.31 BINR-27.49%
3.19 BINR+66.16%
1.92 BINR+13.13%
1.70 BINR-5.14%
1.79 BINR-8.67%
1.96 BINR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Neuland Laboratories Stock analysis

What does Neuland Laboratories do? Neuland Laboratories Ltd. generates revenue through the manufacture and export of bulk pharmaceutical ingredients and intermediates for the generics industry. The company operates in a single segment focused on active pharmaceutical ingredients (APIs) and allied services, with two business verticals: generic drug substances (GDS) and custom manufacturing solutions (CMS). Its products include Levetiracetam, Mirtazapine, Ciprofloxacin, Enalapril, Sotalol, and Labetalol, which are supplied to both domestic and international markets. The firm provides end-to-end chemistry solutions for the pharmaceutical industry, covering synthesis of library compounds, NCEs, and advanced intermediates across clinical and commercial stages. The company's primary customers are pharmaceutical firms requiring APIs and intermediates for generic drugs, with a focus on global markets. Neuland Laboratories Ltd. serves as a solution provider for chemistry needs, offering services from early-stage development to commercial production. The business model emphasizes tailored manufacturing services under CMS, alongside standardized GDS products, catering to the full lifecycle of pharmaceutical development and production. Revenue streams are derived from the sale of specific APIs like Levetiracetam and Mirtazapine, as well as custom manufacturing services for complex chemical processes. The firm's dual verticals allow it to address diverse market demands, with GDS targeting cost-effective generic drug production and CMS focusing on specialized, high-value manufacturing solutions for pharmaceutical clients. Neuland Laboratories is one of the most popular companies on Eulerpool.

Debt Details

Understanding Neuland Laboratories's Debt Structure

Neuland Laboratories's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Neuland Laboratories's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Neuland Laboratories’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Neuland Laboratories’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Neuland Laboratories stock

Debt of Neuland Laboratories is 3.01 B INR in 2026.

Debt of Neuland Laboratories changed from 1.57 B INR to 3.01 B INR, representing a 91.73% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Debt Neuland Laboratories since 2006 – with annual values, charts, and detailed analysis.

Debt's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's Neuland Laboratories historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Neuland Laboratories

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Neuland Laboratories